WHO study on Prevention of REcurrences of Myocardia (WHO-PREMISE)

Bulletin of the World Health Organization 83, 820-9

Citation Report

#	Article	IF	CITATIONS
1	Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet, The, 2006, 368, 679-686.	13.7	229
2	Stroke Prevention in Poor Countries. Stroke, 2007, 38, 2871-2872.	2.0	49
3	Reducing The Growing Burden Of Cardiovascular Disease In The Developing World. Health Affairs, 2007, 26, 13-24.	5.2	234
4	The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countries. Bulletin of the World Health Organization, 2007, 85, 279-288.	3.3	380
5	Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischaemia in women than in men. Heart, 2007, 94, 408-413.	2.9	77
6	Is a multidrug regimen cost-effective for the prevention of cardiovascular disease in resource-poor countries?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 130-132.	3.3	O
7	Health Care Delivery for Coronary Heart Disease in India? Where Are We Headed?. The American Heart Hospital Journal, 2007, 5, 32-37.	0.2	19
8	Perspectives on the management of coronary artery disease in India. Heart, 2007, 93, 1334-1338.	2.9	24
9	Beliefs about health, smoking, and future smoking cessation among South Korean men hospitalized for cardiovascular disease. Heart and Lung: Journal of Acute and Critical Care, 2007, 36, 339-347.	1.6	15
10	Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet, The, 2007, 370, 2054-2062.	13.7	293
11	Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean. Lancet Neurology, The, 2007, 6, 362-372.	10.2	188
12	Acute treatment and long-term management of stroke in developing countries. Lancet Neurology, The, 2007, 6, 553-561.	10.2	146
13	Preventing stroke: saving lives around the world. Lancet Neurology, The, 2007, 6, 182-187.	10.2	1,151
14	Achieving global access to heart rhythm therapies in the next decade: A tangible goal. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 163-168.	1.3	4
15	The patterns of antihypertensive drug prescription by cardiologists in Kerman province of Iran, 2006. Pharmacoepidemiology and Drug Safety, 2008, 17, 180-185.	1.9	9
16	Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurology, The, 2008, 7, 812-826.	10.2	960
17	Global Inequalities in Access to Cardiovascular Health Care. Journal of the American College of Cardiology, 2008, 52, 1817-1825.	2.8	126
18	Changes in lipid profile of patients referred to a cardiac rehabilitation program. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 467-472.	2.8	26

#	Article	IF	CITATIONS
19	Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Vascular Health and Risk Management, 2009, 5, 1007.	2.3	38
20	Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India. Circulation, 2009, 119, 1950-1955.	1.6	61
21	Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 101-110.	3.3	64
22	Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurology, The, 2009, 8, 345-354.	10.2	823
23	Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials, 2009, 10, 5.	1.6	672
24	Conduct of clinical trials in developing countries: a perspective. Current Opinion in Cardiology, 2009, 24, 295-300.	1.8	33
25	Polypill: Lights and Shadows. Current Hypertension Reports, 2010, 12, 276-281.	3.5	7
26	Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovascular Disorders, 2010, 10, 25.	1.7	122
27	Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries. Current Problems in Cardiology, 2010, 35, 72-115.	2.4	793
28	Pre-hospital ECG for acute coronary syndrome in urban India: A cost-effectiveness analysis. BMC Cardiovascular Disorders, 2010, 10, 13.	1.7	16
29	Stroke in Developing Countries: Epidemiology, Impact and Policy Implications. Development Policy Review, 2010, 28, 693-709.	1.8	22
30	The policy agenda for prevention and control of non-communicable diseases. British Medical Bulletin, 2010, 96, 23-43.	6.9	68
31	Dietary Vaccenic Acid Has Antiatherogenic Effects in LDLrâ^'/â^' Mice. Journal of Nutrition, 2010, 140, 18-24.	2.9	95
32	The Polypill in the Prevention of Cardiovascular Diseases. Circulation, 2010, 122, 2078-2088.	1.6	152
33	Antiplatelet Therapy in Coronary Heart Disease Prevention. Cardiology Clinics, 2011, 29, 71-85.	2.2	10
34	Cardiovascular research in India: A perspective. American Heart Journal, 2011, 161, 431-438.	2.7	6
35	The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. American Heart Journal, 2011, 162, 811-817.e1.	2.7	34
36	Knowledge Gaps in Stroke Care: Results of a Survey of Family Physicians in Pakistan. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 282-286.	1.6	11

#	ARTICLE	IF	CITATIONS
37	Polypill and Global Cardiovascular Health Strategies. Seminars in Thoracic and Cardiovascular Surgery, 2011, 23, 24-29.	0.6	24
38	Chronic diseases and injuries in India. Lancet, The, 2011, 377, 413-428.	13.7	328
39	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, The, 2011, 378, 1231-1243.	13.7	803
40	Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. Current Cardiovascular Risk Reports, 2011, 5, 280-286.	2.0	O
41	Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I). BMC Public Health, 2011, 11, 186.	2.9	11
42	Are We There Yet?. Circulation: Heart Failure, 2011, 4, 682-684.	3.9	0
43	High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bulletin of the World Health Organization, 2011, 89, 92-101.	3.3	105
44	The cardiovascular polypill in high-risk patients. European Journal of Preventive Cardiology, 2012, 19, 1234-1242.	1.8	23
45	Knowledge, attitudes and current practice of Jordanian family physicians about prescribing aspirin in primary and secondary prevention of vascular diseases: a self-reported survey. European Journal of Cardiovascular Nursing, 2012, 11, 9-13.	0.9	4
46	Posthospital Heart-Healthy Behaviors in Adults With Comorbid Diabetes. Clinical Nursing Research, 2012, 21, 327-349.	1.6	3
47	Gaps in Capacity in Primary Care in Low-Resource Settings for Implementation of Essential Noncommunicable Disease Interventions. International Journal of Hypertension, 2012, 2012, 1-7.	1.3	103
48	Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2012, , .		1
49	Maximizing Therapeutic Envelope for Prevention of Cardiovascular Disease: Role of Polypill. Mount Sinai Journal of Medicine, 2012, 79, 683-688.	1.9	5
50	Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians' survey in China. European Journal of Preventive Cardiology, 2012, 19, 991-998.	1.8	13
51	Coronary artery disease in Africa and the Middle East. Therapeutics and Clinical Risk Management, 2012, 8, 65.	2.0	77
52	Disparities between Prescribing of Secondary Prevention Therapies for Stroke and Coronary Artery Disease in General Practice. International Journal of Stroke, 2012, 7, 649-654.	5.9	20
53	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. International Journal of Cardiology, 2013, 170, 30-35.	1.7	29
54	Lipid profile in Egyptian patients with coronary artery disease. Egyptian Heart Journal, 2013, 65, 79-85.	1.2	9

#	Article	IF	CITATIONS
55	Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. BMC Public Health, 2013, 13, 1135.	2.9	51
56	Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. European Heart Journal, 2013, 34, 121-129.	2.2	193
57	Inequalities in non-communicable diseases and effective responses. Lancet, The, 2013, 381, 585-597.	13.7	508
58	Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease. Indian Heart Journal, 2013, 65, 250-255.	0.5	3
59	Scaling Up Chronic Disease Prevention Interventions in Lower- and Middle-Income Countries. Annual Review of Public Health, 2013, 34, 317-335.	17.4	52
60	The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2013, 20, 771-778.	1.8	16
61	Global Cardiovascular Therapy. , 2013, , 75-82.		0
62	Association between underweight and taste sensitivity in middle―to oldâ€øged nursing home residents in <scp>S</scp> ri <scp>L</scp> anka: a crossâ€øectional study. Journal of Oral Rehabilitation, 2013, 40, 854-863.	3.0	9
63	Analyzing Recent Coronary Heart Disease Mortality Trends in Tunisia between 1997 and 2009. PLoS ONE, 2013, 8, e63202.	2.5	41
64	Learning lessons from operational research in infectious diseases: can the same model be used for noncommunicable diseases in developing countries?. Advances in Medical Education and Practice, 2014, 5, 469.	1.5	4
65	Rationale and design of a randomized controlled trial evaluating community health worker–based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD). American Heart Journal, 2014, 168, 690-697.	2.7	19
66	Burden of Stroke in Egypt: Current Status and Opportunities. International Journal of Stroke, 2014, 9, 1105-1108.	5.9	43
67	The significance of gender in patients administered coronary angiography with respect to smoking, peripheral arterial disease, diabetes mellitus and the procedure used. Journal of Evaluation in Clinical Practice, 2014, 20, 1124-1128.	1.8	1
69	Coronary artery calcium and polypill therapy. Nature Reviews Cardiology, 2014, 11, 7-8.	13.7	4
70	Global availability of cardiac rehabilitation. Nature Reviews Cardiology, 2014, 11, 586-596.	13.7	156
71	Global Perspective on Acute Coronary Syndrome. Circulation Research, 2014, 114, 1959-1975.	4.5	187
72	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	2.0	3,891
73	Future of Polypill Use for the Prevention of Cardiovascular Disease and Strokes. American Journal of Cardiology, 2014, 114, 641-645.	1.6	13

#	Article	lF	Citations
75	Promoting Cardiovascular Health Worldwide: Strategies, Challenges, and Opportunities. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 724-730.	0.6	21
76	Long-term Adherence to National Guidelines for Secondary Prevention of Ischemic Stroke: A Prospective Cohort Study in a Public Hospital in Chile. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 490-495.	1.6	5
77	Invasive surgery reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction. Journal of Cellular and Molecular Medicine, 2015, 19, 2655-2663.	3.6	11
78	Global burden of CVD: focus on secondary prevention of cardiovascular disease. International Journal of Cardiology, 2015, 201, S1-S7.	1.7	219
79	Understanding physicians' perceived barriers to screening and patient education to reduce stroke risk in community health centers in Indonesia. Journal of Communication in Healthcare, 2015, 8, 143-150.	1.5	11
80	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. Heart, 2015, 101, 279-286.	2.9	14
81	Management and outcomes of acute ST-segment-elevation myocardial infarction at a tertiary-care hospital in Sri Lanka: an observational study. BMC Cardiovascular Disorders, 2015, 15, 1.	1.7	50
82	Uses of Herbals in Cardiac Diseases. , 2015, , 515-529.		3
83	Quality of inpatient care in public and private hospitals in Sri Lanka. Health Policy and Planning, 2015, 30, i46-i58.	2.7	18
84	Polypill: Progress and Challenges to Global Useâ€"Update on the Trials and Policy Implementation. Current Cardiology Reports, 2015, 17, 121.	2.9	10
85	Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. Health Affairs, 2015, 34, 1538-1545.	5.2	42
87	Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practiceâ€"Can We Do Better?. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 58.	0.9	8
88	Prevalence, treatments and outcomes of coronary artery disease in Indians: A systematic review. Indian Heart Journal, 2015, 67, 302-310.	0.5	29
89	Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan. Journal of the Formosan Medical Association, 2015, 114, 1000-1007.	1.7	16
90	Cardiovascular health awareness and the effect of an educational intervention on school-aged children in a rural district of India. Indian Heart Journal, 2016, 68, 43-47.	0.5	15
91	Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. Circulation, 2016, 133, 2076-2085.	1.6	122
92	Cardiovascular Diseases in India. Circulation, 2016, 133, 1605-1620.	1.6	544
93	Cardiac Rehabilitation Delivery Model for Low-Resource Settings: An International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. Progress in Cardiovascular Diseases, 2016, 59, 303-322.	3.1	104

#	Article	IF	Citations
94	Polypill. Journal of Cardiovascular Medicine, 2016, 17, 783-792.	1.5	4
95	Where to now in cardiovascular disease prevention. Atherosclerosis, 2016, 251, 483-489.	0.8	2
96	Coronary artery disease and diabetes mellitus. Journal of Taibah University Medical Sciences, 2016, 11, 330-338.	0.9	8
97	Non-physician health workers for improving adherence to medications and healthy lifestyle following acute coronary syndrome: 24-month follow-up study. Indian Heart Journal, 2016, 68, 832-840.	0.5	16
98	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	772
99	Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension. Current Hypertension Reports, 2016, 18, 14.	3.5	8
101	Improving physicians' performance with a stroke CDSS: A cognitive fit design approach. Computers in Human Behavior, 2016, 54, 577-586.	8.5	10
102	Ruminant and industrial trans-fatty acid uptake in the heart. Journal of Nutritional Biochemistry, 2016, 31, 60-66.	4.2	12
103	Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation, 2016, 133, 742-755.	1.6	78
104	Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 244-253.	11.4	92
105	Targeting danger-associated molecular patterns after myocardial infarction. Expert Opinion on Therapeutic Targets, 2016, 20, 223-239.	3.4	48
106	A study on the availability, price and affordability of drugs for preventing and treating cardiovascular diseases based on information from online pharmacies in China. Drugs and Therapy Perspectives, 2017, 33, 41-46.	0.6	0
107	The polypill approach – An innovative strategy to improve cardiovascular health in Europe. BMC Pharmacology & Coxicology, 2017, 18, 10.	2.4	14
108	Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. International Journal of Cardiology, 2017, 230, 577-584.	1.7	96
109	Prevalence and control of cardiovascular risk factors in stable coronary artery outpatients in India compared with the rest of the world: An analysis from international CLARIFY registry. Indian Heart Journal, 2017, 69, 447-452.	0.5	9
110	Role of the polypill for secondary prevention in ischaemic heart disease. European Journal of Preventive Cardiology, 2017, 24, 44-51.	1.8	17
111	Secondary prevention of cardiovascular disease: Unmet medical need, implementation and innovation. European Journal of Preventive Cardiology, 2017, 24, 5-7.	1.8	8
112	Unfavourable risk factor control after coronary events in routine clinical practice. BMC Cardiovascular Disorders, 2017, 17, 40.	1.7	16

#	ARTICLE	IF	Citations
113	Ensuring Patient-Centered Access to Cardiovascular Disease Medicines in Low-Income and Middle-Income Countries Through Health-System Strengthening. Cardiology Clinics, 2017, 35, 125-134.	2.2	19
114	Quality assurance and the need to evaluate interventions and audit programme outcomes. European Journal of Preventive Cardiology, 2017, 24, 123-128.	1.8	23
115	How is Indonesia coping with its epidemic of chronic noncommunicable diseases? A systematic review with meta-analysis. PLoS ONE, 2017, 12, e0179186.	2.5	50
116	Cut stroke in half: Polypill for primary prevention in stroke. International Journal of Stroke, 2018, 13, 633-647.	5.9	29
117	Prevention of cardiovascular disease: Much more is needed. European Journal of Preventive Cardiology, 2018, 25, 1083-1086.	1.8	11
118	Using mHealth tools to improve access, coverage and treatment of uninsured people with high cardiovascular disease risk in Argentina: a study protocol for a pragmatic cluster randomised trial. BMJ Innovations, 2018, 4, 135-141.	1.7	3
120	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. Expert Opinion on Pharmacotherapy, 2018, 19, 1857-1865.	1.8	16
121	Adherence to Mediterranean dietary pattern in female adolescents. Nutrition and Food Science, 2018, 48, 722-732.	0.9	2
122	Low quality cardiovascular care is important coronary risk factor in India. Indian Heart Journal, 2018, 70, S419-S430.	0.5	17
123	Disparities in the Use of Cardiac Rehabilitation after a Myocardial Infarction in the United States. Journal of Clinical Medicine, 2019, 8, 1006.	2.4	5
124	Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China. PLoS ONE, 2019, 14, e0223769.	2.5	8
125	Risk factors for nutrition-related chronic disease among adults in Indonesia. PLoS ONE, 2019, 14, e0221927.	2.5	8
126	An Educational Intervention to Improve Statin Use: Cluster RCT at the Primary Care Level in Argentina. American Journal of Preventive Medicine, 2019, 57, 95-105.	3.0	7
127	Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. Diabetes Research and Clinical Practice, 2019, 151, 96-105.	2.8	8
128	Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease. BMC Cardiovascular Disorders, 2019, 19, 71.	1.7	24
129	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
130	Are there gender differences in acute management and secondary prevention of acute coronary syndromes in Barbados? A cohort study. BMJ Open, 2019, 9, e025977.	1.9	5
131	Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon. BMC Health Services Research, 2019, 19, 973.	2.2	6

#	ARTICLE	IF	CITATIONS
132	Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs. BMC Medicine, 2019, 17, 209.	5.5	34
133	Meditation and Secondary Prevention of Depression and Anxiety in Heart Disease: a Systematic Review. Mindfulness, 2019, 10, 1-14.	2.8	12
134	Secondary CV Prevention in South America in a Community Setting: The PURE Study. Global Heart, 2017, 12, 305.	2.3	35
135	Compliance to secondary prevention strategies for coronary artery disease: a hospital-based cross-sectional survey from Ernakulam, South India. BMJ Open, 2020, 10, e037618.	1.9	3
136	Primary and Secondary Prevention ofÂlschemic Stroke and CerebralÂHemorrhage. Journal of the American College of Cardiology, 2020, 75, 1804-1818.	2.8	189
137	Cardiometabolic Risk Factors in Pregnancy and Implications for Long-Term Health: Identifying the Research Priorities for Low-Resource Settings. Frontiers in Cardiovascular Medicine, 2020, 7, 40.	2.4	9
138	Trends in Secondary Prevention of Coronary Heart Disease in Tunisia: Prevention of Recurrences of MI and Stroke. Global Heart, 2020, 7, 361.	2.3	5
139	Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. European Journal of Preventive Cardiology, 2022, 29, 383-395.	1.8	40
140	Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology. Frontiers in Pharmacology, 2020, 11, 595008.	3.5	8
141	The ICF Classification System to Assess Risk Factors for CVD in Secondary Prevention after Ischemic Stroke and Intracerebral Hemorrhage. Medicina (Lithuania), 2021, 57, 190.	2.0	4
142	Epidemiological profile, management and outcomes of patients with acute coronary syndrome: Single centre experience from a tertiary care hospital in North India. Indian Heart Journal, 2021, 73, 174-179.	0.5	11
143	Risk Factors for the Recurrence of CVD Incidents in Post-Stroke Patients over a 5-Year Follow-Up Period Based on the ICF Classification. International Journal of Environmental Research and Public Health, 2021, 18, 6021.	2.6	1
144	Missed opportunities in coronary artery disease: reflection on practice to improve patient outcomes. Coronary Artery Disease, 2022, 33, 233-238.	0.7	6
145	Routine' versus  Smart Phone Application Based – Intense' follow up of patients with acute coro syndrome undergoing percutaneous coronary intervention: Impact on clinical outcomes and patient satisfaction. IJC Heart and Vasculature, 2021, 35, 100832.	nary 1.1	4
146	Effects of sociodemographic and socioeconomic factors on stroke development in Lebanese patients with atrial fibrillation: a cross-sectional study. F1000Research, 2021, 10, 793.	1.6	3
147	Barriers to medication adherence in a rural-urban dual economy: a multi-stakeholder qualitative study. BMC Health Services Research, 2021, 21, 799.	2.2	7
148	The incidence of acute myocardial infarction after elective spinal fusions or joint replacement surgery in the United States: a large-scale retrospective observational cohort study in 322,585 patients. Patient Safety in Surgery, 2021, 15, 30.	2.3	3
149	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. Digestive Diseases and Sciences, 2021, , 1.	2.3	4

#	Article	IF	CITATIONS
150	Thirty-day outcomes and predictors of mortality following acute myocardial infarction in northern Tanzania: A prospective observational cohort study. International Journal of Cardiology, 2021, 342, 23-28.	1.7	3
151	Public Sector Capacity to Prevent and Control of Noncommunicable Diseases in Twelve Low- and Middle-Income Countries Based on WHO-PEN Standards: A Systematic Review. Health Services Insights, 2021, 14, 117863292098623.	1.3	11
152	The Global Burden of Stroke. , 2011, , 279-289.		6
153	An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ("Polypillâ€) in People with Raised Cardiovascular Risk. PLoS ONE, 2011, 6, e19857.	2.5	114
154	A Comparative Assessment of Non-Laboratory-Based versus Commonly Used Laboratory-Based Cardiovascular Disease Risk Scores in the NHANES III Population. PLoS ONE, 2011, 6, e20416.	2.5	51
155	Characteristics of High Risk People with Cardiovascular Disease in Chinese Rural Areas: Clinical Indictors, Disease Patterns and Drug Treatment. PLoS ONE, 2013, 8, e54169.	2.5	15
156	Determinants for Achieving the LDL-C Target of Lipid Control for Secondary Prevention of Cardiovascular Events in Taiwan. PLoS ONE, 2015, 10, e0116513.	2.5	33
157	Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program. PLoS ONE, 2016, 11, e0157925.	2.5	26
158	Stroke prevention and control in Brazil: missed opportunities. Arquivos De Neuro-Psiquiatria, 2015, 73, 733-735.	0.8	5
159	Costs and Cost-Effectiveness of Interventions and Policies to Prevent and Treat Cardiovascular and Respiratory Diseases., 2017,, 349-367.		7
160	Management of Hypertension and Dyslipidemia for Primary Prevention of Cardiovascular Disease., 2017,, 389-404.		9
161	Ischemic Heart Disease: Cost-Effective Acute Management and Secondary Prevention., 2017,, 135-155.		8
162	EpidemiologÃa del sÃndrome coronario agudo. Medicina UPB, 2020, 39, 49-56.	0.1	2
163	Hepatitis B virus infection and risk of coronary artery disease: a meta-analysis. Annals of Translational Medicine, 2016, 4, 423-423.	1.7	16
164	Socioeconomic status, cardiac risk factors, and cardiovascular disease: A novel approach to determination of this association. ARYA Atherosclerosis, 2019, 15, 260-266.	0.4	9
165	Review of Rationale, Design, and Initial Findings: Tehran Lipid and Glucose Study. International Journal of Endocrinology and Metabolism, 2018, In Press, e84777.	1.0	52
166	Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: A cross-sectional study of nationally representative surveys. PLoS Medicine, 2021, 18, e1003841.	8.4	23
167	Changing Lifestyle Behaviors to Improve the Prevention and Management of Cardiovascular Disease. , $2015, 118.$		0

#	Article	IF	Citations
168	Changing Lifestyle Behaviors to Improve the Prevention and Management of Cardiovascular Disease., 2016,, 1077-1094.		O
169	Elevated fasting blood glucose, but not obesity, is associated with coronary artery disease in patients undergoing elective coronary angiography in a referral hospital in Jordan. Annals of Saudi Medicine, 2018, 38, 111-117.	1.1	1
170	Study of awareness of risk factors and attitudes towards health in patients with coronary heart disease. New rehabilitation counseling technology: the first experience. Profilakticheskaya Meditsina, 2019, 22, 114.	0.6	0
171	Cerebro-Cardiovascular Diseases., 2020,, 535-623.		o
172	Impact of Literacy on the Prevalence, Awareness, Treatment and Control of Hypertension in Iran. Journal of Cardiovascular and Thoracic Research, 2012, 4, 37-40.	0.9	5
173	Treating to protect: current cardiovascular treatment approaches and remaining needs. Medscape Journal of Medicine, 2008, 10 Suppl, S3.	0.6	1
174	Impact of literacy on the prevalence, awareness, treatment and control of hypertension in adults in Golestan Province (northern Iran). Caspian Journal of Internal Medicine, 2013, 4, 580-4.	0.2	11
175	Medicines as a Service: A New Commercial Model for Big Pharma in the Postblockbuster World. Rand Health Quarterly, 2012, 2, 13.	0.5	1
176	The Recommended Food Score and Healthy Nordic Food Index in cardiovascular disease and stroke: A systematic review. ARYA Atherosclerosis, 2020, 16, 248-257.	0.4	1
177	Gender differences in lifestyle management among coronary patients and the association with education and age: results from the ESC EORP EUROASPIRE V registry. European Journal of Cardiovascular Nursing, 2022, 21, 717-723.	0.9	1
178	Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement. Irish Journal of Medical Science, 2022, 191, 2569-2577.	1.5	1
179	Assessment of CVD Risk Factors in Secondary Prevention after Ischemic Stroke Using the ICF. International Journal of Environmental Research and Public Health, 2022, 19, 3368.	2.6	2
180	Prognostic Outcomes in Acute Myocardial Infarction Patients Without Standard Modifiable Risk Factors: A Multiethnic Study of 8,680 Asian Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 869168.	2.4	24
181	Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. The Lancet Global Health, 2022, 10, e369-e379.	<b>6.</b> 3	41
183	Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017–2020. European Journal of Preventive Cardiology, 2022, 29, 1830-1838.	1.8	13
184	Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis. Global Heart, 2022, 17, 37.	2.3	2
185	Cardiovascular diseases and diabetes mellitus. The European Research Journal, 2022, 8, 541-549.	0.3	1
186	Diabetes Melitus tipe 2 sebagai faktor risiko penyakit jantung koroner (PJK) di RSUD Raden Mattaher Jambi tahun 2019. , 2021, 3, 249-256.		0

#	Article	IF	CITATIONS
187	Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac Rehabilitation. , 0, 2, .		1
188	Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Cureus, 2023, , .	0.5	1